MRNA vs TERN

Moderna maintains a compelling, high-risk 10x growth potential within 3-5 years, primarily driven by its validated mRNA platform and an ambitious, diverse pipeline. The market cap has surged by 23% in 18 days to $19.65B, reflecting strong positive market sentiment and validation. This re-rating is likely due to robust early indicators for mRESVIA (RSV vaccine) market penetration and/or significant...

Terns Pharmaceuticals (TERN) maintains a compelling high-risk, high-reward investment profile, with its score remaining consistent given no material changes since the last analysis. The core thesis is anchored on TERN-701's strong Phase 2 data in B-cell malignancies from late 2025, validating its highly selective BTK inhibitor profile and supporting a strategic pivot towards oncology. This offers ...